12:00 AM
Nov 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ISIS-STAT3Rx: Preliminary Phase I data

Preliminary data from an open-label, dose-escalation, U.S. Phase I trial in solid tumor and lymphoma patients who relapsed after or were refractory to multiple chemotherapy regimens showed that ISIS-STAT3Rx was well tolerated. In 2 patients with diffuse large B cell...

Read the full 179 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >